VPAC1 Antibody (B-4): sc-377152

VPAC1 Antibody (B-4) is a mouse monoclonal IgG2a kappa light chain antibody that detects VPAC1 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). VPAC1 (B-4) antibody is available in non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. VPAC1 protein plays a crucial role in mediating the effects of vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP), which belong to a superfamily of peptide hormones including glucagon, secretin, and growth hormone-releasing hormone. These hormones work through three G-protein coupled receptors: VPAC1, VPAC2, and PACAP receptor (PAC1-R). VPAC1 and VPAC2 show equal affinities for both VIP and PACAP, activating adenylyl cyclase for various cellular signaling pathways. VPAC1 expression is abundant in brain and T cells, where VPAC1 modulates neuronal differentiation and T cell activation, highlighting VPAC1′s importance in neuroimmunology. PACAP receptor, a seven transmembrane protein, generates at least eight isoforms through alternative splicing, each with distinct signaling pathways and expression patterns, demonstrating the complexity of VPAC receptor system in physiological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VPAC1 Antibody (B-4) References:

1. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.  |  Vaudry, D., et al. 2000. Pharmacol Rev. 52: 269-324. PMID: 10835102
2. Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice.  |  Shen, S., et al. 2000. Proc Natl Acad Sci U S A. 97: 11575-80. PMID: 11027354
3. Expression of vasoactive intestinal peptide (VIP) receptors in human uterus.  |  Bajo, AM., et al. 2000. Peptides. 21: 1383-8. PMID: 11072126
4. Vasoactive intestinal peptide: cardiovascular effects.  |  Henning, RJ. and Sawmiller, DR. 2001. Cardiovasc Res. 49: 27-37. PMID: 11121793
5. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.  |  Lara-Marquez, M., et al. 2001. J Immunol. 166: 2522-30. PMID: 11160313
6. Regulation of vasoactive intestinal peptide receptor expression in developing nervous systems.  |  Karacay, B., et al. 2000. Ann N Y Acad Sci. 921: 165-74. PMID: 11193820
7. Pituitary adenylate cyclase-activating polypeptide (PACAP) and its receptors in the brain.  |  Shioda, S. 2000. Kaibogaku Zasshi. 75: 487-507. PMID: 11197592
8. VPAC1 is a cellular neuroendocrine receptor expressed on T cells that actively facilitates productive HIV-1 infection.  |  Branch, DR., et al. 2002. AIDS. 16: 309-19. PMID: 11834941
9. VPAC1 overexpression is associated with poor differentiation in colon cancer.  |  Liu, S., et al. 2014. Tumour Biol. 35: 6397-404. PMID: 24671823
10. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.  |  Jayawardena, D., et al. 2017. Am J Physiol Gastrointest Liver Physiol. 313: G16-G25. PMID: 28385693
11. VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen.  |  Truong, H., et al. 2018. World J Urol. 36: 719-726. PMID: 29541892
12. VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism.  |  Tang, B., et al. 2019. Oncogene. 38: 3946-3961. PMID: 30692637

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VPAC1 Antibody (B-4) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-VPAC1 Antibody (B-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VPAC1 Antibody (B-4) Specifications

Alternate Product Name: VPAC1

Product Clone Name: B-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 31-160

Epitope Target: VPAC1

Epitope Species: human

Product Reactivity/Detection: VPAC1

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for VPAC1 Antibody (B-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin